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Abstract
Known genetic loci explain only a small proportion of the familial relative risk of colorectal
cancer (CRC). We conducted the largest genome-wide association study in East Asians with
14,963 CRC cases and 31,945 controls and identified six new loci associated with CRC risk (P =
3.42 × 10−8 to 9.22 × 10−21) at 10q22.3, 10q25.2, 11q12.2, 12p13.31, 17p13.3 and 19q13.2. Two
of these loci map to genes (TCF7L2 and TGFB1) with established roles in colorectal
tumorigenesis. Four other loci are located in or near genes involved in transcription regulation
(ZMIZ1), genome maintenance (FEN1), fatty acid metabolism (FADS1 and FADS2), cancer cell
motility and metastasis (CD9) and cell growth and differentiation (NXN). We also found
suggestive evidence for three additional loci associated with CRC risk near genome-wide
significance at 8q24.11, 10q21.1 and 10q24.2. Furthermore, we replicated 22 previously reported
CRC loci. Our study provides insights into the genetic basis of CRC and suggests new biological
pathways.
Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality worldwide 1.
It is well established that genetic factors play a significant role in the etiology of CRC 2, 3.
Deleterious germline mutations in known susceptibility genes, notably APC (adenomatous
polyposis coli), MLH1, MSH2, MSH6 and PMS2, confer high risk of CRC in hereditary
cancer syndromes 3–6. Most sporadic CRC cases, however, do not carry these high-
penetrance mutations 3, 4. Since 2007, genome-wide association studies (GWAS) and
subsequent fine-mapping analyses conducted in European descendants have identified 21
low-penetrance susceptibility loci associated with CRC risk 7–17. Together, these common
loci explain less than 10% of the familial relative risk of CRC in European
populations 13, 14. In a GWAS of 7,456 CRC cases and 11,671 controls conducted as part of
the Asia Colorectal Cancer Consortium, we identified three new loci at 5q31.1 (near PITX1),
12p13.32 (near CCND2) and 20p12.3 (near HAO1) associated with CRC risk 18. In addition,
we discovered a new risk variant in the SMAD7 gene associated with CRC among East
Asians 19. Over the past two years, we have doubled the sample size in the Asia Colorectal
Cancer Consortium and conducted a four-stage GWAS including 14,963 CRC cases and
31,945 controls to identify additional susceptibility loci for CRC.
RESULTS
We performed a fixed-effects meta-analysis to evaluate approximately 2.4 million
genotyped or imputed SNPs in 22 autosomes from five GWAS (stage 1) conducted in China,
Japan and South Korea, totaling 2,098 CRC cases and 6,172 cancer-free controls
(Supplementary Tables 1 and 2). There was little evidence of population stratification in
these studies (Supplementary Figs. 1 and 2), with genomic inflation factor λ <1.04 in any of
the five studies and the meta-analysis (λ1000 =1.01). We selected 8,539 SNPs showing
evidence of association with CRC risk (P <0.05) according to pre-specified criteria
(ONLINE METHODS). We also included the 31 risk variants identified by previous
GWAS 7–20, resulting in a total of 8,569 SNPs. Of them, 7,113 SNPs were successfully
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designed using Illumina Infinium assays as part of a large genotyping effort for multiple
projects. Using this customized array, we genotyped an independent set of 3,632 CRC cases
and 6,404 controls recruited in three studies (stage 2) conducted in China. After quality
control exclusions, 6,899 SNPs remained for the analysis in 3,519 cases and 6,275 controls.
We evaluated associations between CRC risk and these SNP in each study separately and
then performed a fixed-effects meta-analysis to obtain the summary estimates. Again, we
observed little evidence of population stratification either in the three studies individually (λ
<1.05) or combined (λ = 1.05, λ1000 = 1.01) (Supplementary Fig. 3). In a meta-analysis of
data from stages 1 and 2, we identified 559 SNPs showing evidence of association at P
<0.005. We then evaluated these SNPs using data from a large Japanese CRC GWAS (stage
3) with 2,814 CRC cases and 11,358 controls 20. Thirty SNPs in 25 new loci were associated
with CRC risk at P <0.0001 in the meta-analysis of data from stages 1 to 3 and at P <0.01 in
the meta-analysis of stages 2 and 3. Of them, 29 were successfully genotyped in an
independent sample of 6,532 CRC cases and 8,140 controls from five additional studies
(stage 4) conducted in China, South Korea and Japan.
Newly identified risk loci for CRC
In the meta-analysis of all data for the 29 SNPs from stages 1 to 4 with 14,963 CRC cases
and 31,945 controls, signals from ten SNPs, representing six new loci, showed convincing
evidence for an association with CRC risk at the genome-wide significance level (P
<5×10−8) including: rs704017 at 10q22.3; rs11196172 at 10q25.2; rs174537, rs4246215,
rs174550 and rs1535 at 11q12.2; rs10849432 at 12p13.31; rs12603526 at 17p13.3; and
rs1800469 and rs2241714 at 19q13.2 (Table 1, Supplementary Tables 3 and 4, and
Supplementary Fig. 4). Associations of CRC risk with the top SNPs in each of the six loci
were consistent across almost all studies with no evidence of heterogeneity (Fig. 1). With
the exception of rs10849432 intergenic to 12p13.31, the remaining nine newly identified
risk variants are located in the exonic, promoter, three prime untranslated region (3′-UTR)
or intronic regions of known genes (Table 1). The linkage disequilibrium (LD) blocks (r2
>0.5) tagged by rs704017 (10q22.3), rs174537 (11q12.2), and rs1800469 (19q13.2), each
span multiple genes (Supplementary Table 5). The LD blocks tagged by rs11196172
(10q25.2) and rs12603526 (17p13.3), each lie within a single gene. The LD block tagged by
rs10849432 (12p13.31) does not contain any known genes. Stratification analyses of the
newly identified risk variants by tumor anatomic site (colon, rectum), population (Chinese,
Korean, and Japanese), and sex (men, women) did not reveal any significant heterogeneity
(Supplementary Tables 6 to 8). In addition to the six newly identified loci, three additional
regions also showed an association with CRC risk near genome-wide significance at
8q24.11 (rs6469656, P =5.38×10−8), 10q21.1 (rs4948317, P =7.14×10−8) and 10q24.2
(rs12412391, P =7.41×10−7). Results for all 29 SNPs across stage 1 to stage 4 are presented
in Supplementary Table 3.
We performed conditional analyses for SNPs within a 1-mb region centered on the index
SNPs in each of the six newly identified loci. No second signal was identified at P <0.01
after adjusting for the respective index SNPs (data not shown). Four SNPs at 11q12.2 and
two SNPs at 19q13.2 showed association with CRC risk at P <5×10−8, and thus we
performed haplotype analysis for these two loci using genotype data available for 10,051
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CRC cases and 14,415 controls (stages 2 and 4). Two common haplotypes were found in the
11q12.2 locus, accounting for more than 99% of the haplotypes constructed using the four
highly correlated SNPs. The haplotype with all four risk alleles (frequency =0.574 in
controls) was strongly associated with CRC risk (odds ratio (OR) =1.40, 95% confidence
interval (CI): 1.29–1.51; P =3.69×10−16) (Supplementary Table 9). Similarly, we identified
two common haplotypes in the 19q13.2 locus, accounting for more than 99% of the
haplotypes constructed using the two highly correlated SNPs. The haplotype with the risk
allele in both SNPs (frequency =0.485 in controls) was also associated with increased risk of
CRC (OR=1.16, 95% CI: 1.08–1.26; P =1.18×10−4) (Supplementary Table 10). Therefore,
these analyses did not reveal an independent signal in any of the six newly identified loci.
We examined potential SNP-SNP interactions between the six new risk variants (rs704017,
rs11196172, rs174537, rs10849432, rs12603526, and rs1800469) identified in this study and
also between these six SNPs and the risk variants in 25 previously reported loci
(Supplementary Table 11). Multiplicative interactions were found with suggestive evidence
(P <0.05) for seven pairs of SNPs. None of these interactions, however, remain statistically
significant after correcting for multiple comparisons of 180 tests (adjusted P =0.000277).
We evaluated associations of the ten newly identified SNPs with CRC risk in European
descendants using data from three consortia, the Genetics and Epidemiology of Colorectal
Cancer Consortium (GECCO) 17, the Colorectal Transdisciplinary (CORECT) Study and the
Colon Cancer Family Registry (CCFR) 21, with a total sample size of 16,984 CRC cases and
18,262 controls (Supplementary Table 12). In a meta-analysis of data from these consortia,
all ten SNPs showed associations with CRC risk in the same direction as observed in East
Asians (Table 2). Five SNPs in two loci (10q22.3 and 11q12.2) were associated with CRC
risk at P <0.008 (corrected for multiple comparisons of six loci). The strength of these
associations in Europeans, however, was weaker than in East Asians. Tests for heterogeneity
were statistically significant for risk variants in 11q12.2 and 19q13.2 (P <0.008). The
frequency of the risk allele also differed considerably between Europeans and East Asians
for SNPs in five loci (Supplementary Table 13). For example, rs12603526 is common in
East Asians, whereas the minor allele frequency (MAF) is <0.02 in Europeans. These
differences may partly reflect distinct patterns of LD between the index SNPs and causal
SNPs in these two populations. As expected, LD patterns for most of the newly identified
loci differed considerably between Europeans and East Asians (Supplementary Fig. 5).
Large-scale fine-mapping of these loci will be helpful to identify causal variants.
Putative functional variants and candidate genes
We evaluated and annotated putative functional variants and candidate genes in each of the
six newly identified loci using data from the 1000 Genomes Project 22, HapMap 2 23,
Encyclopedia of DNA Elements (ENCODE) 24, expression quantitative trait locus (eQTL)
databases 25–28, the Catalogue of Somatic Mutations in Cancer (COSMIC) 29, The Cancer
Genome Atlas (TCGA) CRC project 30, Gene Expression Atlas 31, PubMed and OMIM
(ONLINE METHODS). We summarize results below for each locus.
At the 10q25.2 locus, rs11196172 is located in intron 4 of the TCF7L2 gene. The SNP and
other correlated SNPs (r2 >0.5) fall within a strong enhancer activity region and a DNase I
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hypersensitivity site annotated by ENCODE (Supplementary Table 14), suggesting a
potentially functional role for these SNPs. We found that the risk allele of rs11196172 was
significantly associated with increased expression of the TCF7L2 gene (P =0.003) in colon
tumor tissue using TCGA data (Fig. 2). The TCF7L2 gene encodes TCF7L2 (previously
known as TCF4), which is key transcription factor in the Wnt signaling pathway. Aberrant
activation of Wnt signaling is found in more than 90% of CRC 30. TCF7L2 is a known
tumor suppressor for CRC. Loss of TCF7L2 function enhances CRC cell growth, whereas
gain of function suppresses CRC cell growth 32, 33. The TCF7L2 gene is one of the most
frequently mutated genes in CRC, with estimated point mutation rates of approximately 8 to
12.5% 29, 30. Although TCF7L2 is the only gene in this locus (Supplementary Fig 4), we
also found that the risk allele of rs11196172 was significantly associated with increased
expression of the VTI1A gene (P =5.1×10−4) in colon tumor tissue (Fig. 2). The VTI1A gene
is located approximately 131 kb upstream of the TCF7L2 gene and mRNA levels of these
two genes are highly correlated in colon tumor tissues (r =0.71, P <0.0001). Recently, a
recurrent gene fusion of the first three exons of VTI1A to the fourth exon of TCF7L2 has
been found in approximately 3% of colorectal tumors 34. It is possible that the VTI1A gene
may also be involved in the association between rs11196172 and CRC risk.
At the 19q13.2 locus, we identified two perfectly correlated SNPs (rs1800469 and
rs2241714, r2 =1) associated with CRC risk. Of them, rs1800469 has been previously
investigated in relation to CRC risk in many small candidate-gene association studies with
conflicting results 5. We herein provide, for the first time, convincing evidence for this
association through our GWAS. SNP rs1800469 maps to the promoter of the TGFB1 gene,
while rs2241714 is a nonsynonymous SNP that results in an amino acid substitution on
codon 11 of the B9D2 protein. The A allele of rs1800469 has been related to higher levels of
transcription activity of the TGFB1 gene and higher circulating levels of the TGF-β1 protein
than the G allele 35. Both rs1800469 and rs2241714 are in perfect LD with another
nonsynonymous SNP rs1800470, which causes a proline to leucine substitution at codon 10
of the TGF-β1 protein. Although the two nonsynonymous SNPs are predicted to be
tolerant 36 or benign 37, the Pro10 variant of rs1800470 has also been associated with an
increase in gene expression of TGFB1, TGF-β1 protein secretion and circulating levels of
TGF-β1 38–40. While rs2241714 is an eQTL for TGFB1, both rs1800469 and rs2241714 are
also eQTLs for other genes in this locus (Supplementary Table 15). In addition to these three
SNPs, many highly correlated SNPs located in the TGFB1 gene are suggested to have
potentially regulatory functions (Supplementary Table 14). The TGF-β1 protein is a major
member of the TGF-β signaling pathway. Somatic alterations of certain components
(TGFBR2, SMAD4, SMAD2 and SMAD3) in this pathway are estimated to affect almost half
of CRC 41. High-penetrance germline mutations in the SMAD4 gene are known to cause
juvenile polyposis, an autosomal dominant polyposis syndrome with a high risk of CRC 42.
Germline, allele-specific expression of the TGFBR1 gene has also been shown to contribute
to increased risk of CRC 43. To date, GWAS have identified at least six other independent
SNPs that are located in or proximal to genes in the TGF-β signaling pathway (SMAD7,
GREM1, BMP2, BMP4 and RHPN2) 9, 10, 13, 19. Our finding of an association between a
genetic variant in the TGFB1 gene and CRC risk adds further evidence for the critical role of
this pathway in colorectal tumorigenesis.
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At the 11q12.2 locus, the four perfectly correlated SNPs rs174537, rs4246215, rs174550 and
rs1535 lie in intron 24 of MYRF, the 3′-UTR of FEN1, intron 7 of FADS1 and intron 1 of
FADS2, respectively. Of them, rs4246215 is an eQTL for the FEN1 gene in normal
colorectal tissue 44 and is predicted to affect miRNA binding site activity 45. SNP rs174537
is an eQTL for the FADS1 and FADS2 genes in whole blood and other types of tissue
(Supplementary Table 15). Using data from TCGA, we identified a strong correlation of
rs1535 genotypes with FADS2 gene expression (P =1.4×10−5) in colon tumor tissue (Fig. 2).
These findings suggested that the potential function of these SNPs may be mediated through
their effect on their host genes. We also found that the FEN1, FADS1 and FADS2 genes are
all highly expressed in colon tumor tissue compared with normal colon tissue
(Supplementary Table 16). The FEN1 gene encodes flap structure-specific endonuclease 1, a
protein that is essential for DNA repair, replication and degradation and has a critical role in
maintaining genome stability and protecting against carcinogenesis 46. FEN1 mutations have
been found in several human cancers 47. Mouse models with haploinsufficiency of Fen1
showed rapid progression of CRC and reduced survival 48. Two other genes in this locus,
FADS1 and FADS2, respectively encode delta-5 and delta-6 desaturases, which are key
enzymes in polyunsaturated fatty acid metabolism. Of them, delta-6 desaturase is
responsible for the synthesis of arachidonic acid 49, the precursor of prostaglandin E2
(PGE2), which is a key molecule mediating the effect of cyclooxygenase-2 in colorectal
carcinogenesis 50. Notably, SNPs in perfect LD with the risk variants for CRC identified in
this study are strongly associated with circulating arachidonic acid level 49. We have shown
previously that high levels of urinary PGE2 metabolite, a marker of endogenous PGE2
production, is strongly related to elevated risk of CRC 51. Because the LD block of
approximately 190 kb tagged by the four risk variants covers many putatively functional
SNPs that are located in the FEN1, FADS1 and FADS2 genes (Supplementary Table 14 and
Supplementary Fig. 6), it is difficult to pinpoint a single SNP or gene that may be
responsible for the association with CRC risk in this locus. Nevertheless, our study provides
evidence for a potentially significant role of the FEN1, FADS1 and FADS2 genes in the
etiology of CRC.
At the 10q22.3 locus, rs704017 is located in intron 3 of the ZMIZ1-AS1 gene and resides in a
strong enhancer region predicted using ENCODE data (Supplementary Fig. 6 and
Supplementary Table 14). It also maps to a DNase I hypersensitivity site in the Caco-2 CRC
cell line. In addition to the ZMIZ1-AS1 gene, the LD block tagged by rs704017 also includes
the ZMIZ1 gene, which is down-regulated in the Caco-2 and HT-29 CRC cell lines 31. In
line with this, we found in TCGA data that ZMIZ1 gene expression is reduced in colon
tumor tissue compared with normal colon tissue (P =3.28×10−6). In addition, somatic
mutations in the ZMIZ1 gene have been reported in more than 2% of colon tumors 29. While
ZMIZ1-AS1 is a miscRNA gene with unknown function, the ZMIZ1 gene encodes the
protein ZMIZ1, which regulates the activity of several transcription factors, including AR,
SMAD3, SMAD4 and p53. It has been shown that ZMIZ1 may play a broader role in
epithelial cancers, including CRC 52. SNP rs704010, located in intron 1 of the ZMIZ1 gene,
has been associated with breast cancer 53. However, this SNP, which is in weak LD (r2 =
0.09) with the risk variant we identified for CRC, was not associated with CRC in this study
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(data not shown). Given the biologic function of the ZMIZ1 gene, it is possible that this gene
is involved in the association observed in this locus.
At the 12p13.31 locus, rs10849432 maps to a LD block of approximately 52 kb with no
known genes. ENCODE data suggest that rs4764551 and rs4764552, perfectly correlated
with rs10849432, may be located in a strong enhancer region (Supplementary Table 14).
Notably, rs4764551 also maps to a DNase I hypersensitivity site in the HCT-116 CRC cell
line and a binding site of the CTCF protein in the Caco-2 CRC cell line. Using data from
TCGA, we showed that the closest genes to rs10849432, CD9, PLEKHG6 and TNFRSF1A
are all down-regulated in colon tumor tissue (Supplementary Table 16). The CD9 gene
encodes the CD9 antigen, which participates in many cellular processes, including
differentiation, adhesion and signal transduction. Notably, CD9 plays a critical role in the
suppression of cancer cell motility and metastasis 54, and overexpression of the CD9 gene is
associated with favorable prognosis of patients with CRC 55. CD9 is also involved in
suppressing Wnt signaling 56. While function of the PLEKHG6 gene is less clear, somatic
mutations in this gene were found in approximately 2% of colon tumors 29. The protein
encoded by TNFRSF1A is a major receptor for tumor necrosis factor-alpha and is known to
be involved in cytokine-induced senescence in cancer 57. In addition to evidence for the
three nearby genes, we found that rs4764552 is an eQTL for the LTBR gene (Supplementary
Table 15). The LTβR protein plays an essential role in lymphoid organ formation and has
also been linked to cancer 58, including CRC 59. Based on these data, we believe that the
CD9 gene is the most likely candidate to explain the association identified in this locus.
However, the potential role of other genes cannot be ruled out.
At the 17p13.3 locus, rs12603526 lies in intron 1 of the NXN gene, a region covering several
regulatory elements, including a DNase I hypersensitivity site, a strong enhancer region and
a site with an effect on regulatory motifs as annotated by ENCODE (Supplementary Table
14). NXN gene expression was reduced in colon tumor tissue samples included in TCGA (P
=2.83×10−5). Nucleoredoxin, encoded by the NXN gene, has functions related to cell growth
and differentiation 60. Overexpression of the NXN gene has been found to suppress the Wnt
signaling pathway, and dysfunction of nucleoredoxin may cause activation of the
transcription factor T cell factor, accelerated cell proliferation and enhancement of
oncogenicity 61. Further research is needed to determine the causal variant and biologic
mechanism for the association in this locus.
Previously reported CRC loci in East Asians
We evaluated association evidence for 31 SNPs in 25 established CRC susceptibility
loci 7–20 by analyzing data from stages 1 to 3 and our previous GWAS 18, 19 with a total
sample size of up to 11,934 CRC cases and 28,282 controls (Table 3 and Supplementary
Table 17). We found further evidence to support the association for the four loci identified
previously in our GWAS conducted among East Asians (P =1.40×10−10 to 3.05×10−15). Of
the 23 SNPs in the 18 susceptibility loci previously identified by GWAS of European
descendants, 20 showed associations with CRC risk at P <0.05 among East Asians in the
same direction as reported in the original studies 7–17. These included six SNPs in four loci
(1q41, 8q24.21, 10p14 and 18q21.1) with an association at P <5×10−8, six SNPs in six loci
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with an association at P <0.002 (significance level adjusted for multiple comparisons of 24
independent loci), and eight SNPs in eight additional loci with an association at P <0.05.
Three SNPs in three loci were not associated with CRC risk (P >0.05). Given that our study
had a statistical power of >80% to identify an association with an OR of 1.05 at P =0.05 for
SNPs with a MAF of 0.20, it is unlikely that these three SNPs confer a substantial risk of
CRC in East Asian populations. Generally, loci initially identified in Europeans had smaller
ORs in East Asians, with evidence of heterogeneity noted for three SNPs (P <0.002). SNPs
rs6691170 and rs16892766, identified by previous GWAS of European descendants, are not
polymorphic in East Asians and SNP rs5934683 is located in chromosome X. We did not
have data to evaluate the association of these three SNPs with CRC risk in this study.
Familial relative risk explained by established CRC loci
The six newly identified loci in this study explain approximately 2.1% of the familial
relative risk of CRC in East Asians (Supplementary Table 18). The variants, along with the
four SNPs identified in our previous GWAS, explained approximately 4.3% of the familial
relative risk of CRC in East Asians. An additional 3.4% of the familial relative risk in East
Asians can be explained by 18 independent SNPs initially identified in studies conducted
among European descendants and confirmed in this study. Based on per-allele ORs derived
from previously published GWAS 7–18 and this study, we estimate that the SNPs in the 31
loci identified to date explain approximately 9% of the familial relative risk of CRC in
Europeans (Supplementary Table 19), slightly higher than the 7.7% explained in East
Asians.
DISCUSSION
In the largest GWAS conducted to date among East Asians, we identified six new genetic
loci associated with CRC risk and provided suggestive evidence for three additional novel
loci. In addition, we replicated 22 previously reported CRC susceptibility loci. Of the six
newly identified loci, two map to genes (TCF7L2 and TGFB1) that have established roles in
colorectal tumorigenesis. The other four loci are located in or proximal to genes that are
functionally important in transcription regulation (ZMIZ1), genome maintenance (FEN1),
fatty acid metabolism (FADS1 and FADS2), cancer cell motility and metastasis (CD9) and
cell growth and differentiation (NXN). Risk variants at some loci fall within potentially
functional regions and two are associated with expression levels of the TCF7L2 and FADS2
genes. This study expands our current understanding of the genetic basis of CRC risk and
provides evidence for novel genes and biological pathways that may be involved in
colorectal tumorigenesis.
Based on a large twin study conducted in Sweden, Denmark and Finland 2, the heritability
estimated for CRC, breast cancer and prostate cancer was 35%, 27% and 42%, respectively.
To date, more than 70 low-penetrance susceptibility loci have been identified in GWAS for
breast cancer 62 or prostate cancer 63, and these loci together explain approximately 14%
and 30%, respectively, of the familial relative risk of breast cancer and prostate cancer
among European descendants. For CRC, however, only 31 low-penetrance susceptibility
loci have been identified, explaining approximately 9% of the familial relative risk of CRC
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among European descendants. Compared with GWAS of breast cancer and prostate cancer,
studies conducted for CRC have been relatively small. In our study, we evaluated
approximately 7,000 promising variants identified from GWAS in the replication stages,
which represents one of the largest efforts made to date to follow-up genetic variants
identified by GWAS. Six novel loci were identified, representing the largest number of loci
identified for CRC risk in a single study. Although multiple GWAS with sample sizes larger
than this study have been conducted among European descendants 13, 14, 16, we were still
able to identify risk variants with relatively large effect sizes. Our study further highlights
the value of conducting GWAS in non-European populations to discover novel susceptibility
loci for CRC.
In summary, we have identified six new loci associated with CRC risk in this large GWAS
conducted among East Asians. These new loci contain genes with established connections to
colorectal tumorigenesis through major biological pathways such as Wnt and TGF-β
signaling, as well as genes with important biological function that have not yet been well
linked to CRC. Our study considerably expands our knowledge of the genetic landscape of
CRC and provides clues for future studies to characterize the causal variants and functional
mechanisms for these GWAS-identified loci.
ONLINE METHODS
Studies participants
This genome-wide association study (GWAS) was conducted as part of the Asia Colorectal
Cancer Consortium, including a total of 14,963 colorectal cancer (CRC) cases and 31,945
controls of East Asian ancestry from 14 studies conducted in China, South Korea and Japan
(Supplementary Table 1). Specifically, stage 1 (GWAS discovery) consisted of five studies:
Shanghai CRC Study 1 (Shanghai-1, n = 3,102), Shanghai CRC Study 2 (Shanghai-2, n =
908), Guangzhou CRC Study 1 (Guangzhou-1, n = 1,603), Aichi CRC Study 1 (Aichi-1, n
=1,346), and Korean Cancer Prevention Study-II CRC (KCPS-II, n = 1,301). With the
exception of Shanghai-2 for which we added 423 controls from other studies 64, 65, samples
for the remaining four studies were the same as we reported in our previous study 18. Stage 2
consisted of three studies: Shanghai CRC Study 3 (Shanghai-3, n = 6,577), Guangzhou CRC
Study 2 (Guangzhou-2, n = 809), and Guangzhou CRC Study 3 (Guangzhou-3, n = 2,408).
Stage 3 included one study: the BioBank Japan CRC Study (BBJ, n = 14,172). Stage 4
consisted of five studies: Guangzhou CRC Study 4 (Guangzhou-4, n = 1,791), Aichi CRC
Study 2 (Aichi-2, n = 708), Korean-National Cancer Center CRC Study (Korea-NCC, n =
2,721), Seoul CRC Study (Korea-Seoul, n = 1,522), and Hwasun Cancer Epidemiology
Study-Colon and Rectum Cancer (HCES-CRC, n = 7,930). We estimated that our study had
a statistical power of >80% to identify an association with an OR of 1.10 or above at P
<5×10−8 for SNPs with a MAF of as low as 0.30. We evaluated generalizability of the newly
identified associations with CRC risk in European descendants in three consortia including
23 studies (Supplementary Table 13) with a total sample size of 16,984 cases and 18,262
controls recruited in the United States, Europe, Canada and Australia: the Genetics and
Epidemiology of Colorectal Cancer Consortium (GECCO) 17, the Colorectal
Transdisciplinary (CORECT) Study and the Colon Cancer Family Registry (CCFR) 21.
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Summary descriptions of participating studies are presented in Supplementary Note. Study
protocols were approved by the relevant review boards in respective institutions and
informed consents were obtained from all study participants.
Laboratory procedures
Genotyping of samples in stage 1 was conducted as described previously using the following
platforms: Affymetrix Genome-Wide Human SNP Array 6.0, Illumina HumanOmniExpress
BeadChip, Illumina Infinium HumanHap550 BeadChip, Illumina 660W-Quad BeadChip,
Illumina Human610-Quad BeadChip, Illumina Infinium HumanHap610 BeadChip, and
Affymetrix Genome-Wide Human SNP Array 5.0 18, 64–69. We used a uniform quality
control protocol as described in our recent paper 18 to filter samples and SNPs. Genotyping
and quality control methods are also presented in the Supplementary Note. After quality
control exclusions, we obtained 502,145 autosomal SNPs for samples in Shanghai-1,
245,961 SNPs in Shanghai-2, 250,612 SNPs in Guangzhou-1, 232,426 SNPs in Aichi-1, and
312,869 SNPs in KCPS-II (Supplementary Table 2).
Genotyping for 3,632 cases and 6,404 controls in stage 2 was completed using Illumina
Infinium assays as part of the customer add-on content for multiple projects to the Illumina
HumanExome Beadchip (see URLs). Details of array design, genotyping, genotype call and
quality control are provided in the Supplementary Note. Samples were excluded according
to the following criteria: (i) genotype call rate <98%, (ii) genetically identical or duplicated
samples, (iii) sex determined using genetic data inconsistent with epidemiological or clinical
data, (iv) first or second degree relatives, (v) ethnic outliers, or (vi) heterozygosity outliers.
Genetic markers were excluded using the following criteria: (i) MAF = 0, (ii) genotype call
rate <98%, (iii) consistency rate <98% in positive quality control samples, (iv) P for Hardy-
Weinberg equilibrium (HWE) <10−5 in controls or (v) caution SNPs revealed by the Exome
Chip Design group (see URLs). We obtained a final dataset including 6,899 SNPs
genotyped on 3,519 cases and 6,275 controls for this project.
Cases and controls in stage 3 were genotyped using the Illumina HumanHap610-Quad
BeadChip. Quality control filters were based on criteria described previously 20. Methods of
genotyping and quality control procedures are also presented in the Supplementary Note.
After sample and SNP exclusions, we generated a dataset including 2,814 cases and 11,358
controls with 460,463 SNPs.
Stage 4 genotyping for 29 SNPs was conducted using the iPLEX Sequenom MassARRAY
platform according to manufacturer’s protocols at the Vanderbilt Molecular Epidemiology
Laboratory (Nashville, Tennessee, United States). Details of genotyping and quality control
are provided in the Supplementary Note. We filtered out SNPs with (i) genotype call rate
<95%, (ii) genotyping consistency rate <95% in positive control samples, (iii) an unclear
genotype call or (iv) P for HWE <10−5 in controls. The average consistency rate of these
SNPs passing quality control filters was 99.9% with median value 100% in each of the five
participating studies included in this stage.
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Samples in GECCO, CORECT and CCFR were genotyped with Illumina and Affymetrix
Arrays17, 21. Genotyping, quality control and imputation have been reported in
previously 17, 21 and are described in the Supplementary Note.
SNP selection
Selection of SNPs for stage 2 replication was primarily based on the following criteria: (i) P
<0.05 in meta-analysis, (ii) P for heterogeneity >0.0001, (iii) imputation R2 >0.5 in at each
of the included studies, (iv) MAF >0.05 in each of the included studies, (v) SNPs
uncorrelated with established CRC SNPs (defined as r2 <0.2 in HapMap Asian), (vi) SNPs
uncorrelated with other SNPs identified in this project (r2 <0.2) and (vii) data available in at
least two studies (see Supplementary Note). We included multiple SNPs in some regions
with a prior P value of <0.002 or with genes of interest. Risk variants identified from
previously published GWAS were also included in the assay 7–20. In total, 8,569 unique
SNPs were selected. Of them, 7,113 SNPs were successfully designed. For stage 3
replication, we selected 559 SNPs according to criteria: (i) P <0.005 in meta-analysis of data
from stages 1 and 2, (ii) association in the same direction in both stages and (iii) P for
heterogeneity >0.0001. For stage 4, we selected 30 SNPs on the basis of criteria: (i) P
<0.0001 in meta-analysis of stages 1, 2, and 3, (ii) P <0.01 in meta-analysis of stages 2 and
3, (iii) association in the same direction in three stages and (iv) P for heterogeneity >0.0001.
Statistical and bioinformatic analysis
Details of imputation and population substructure evaluation are provided in the
Supplementary Note. Briefly, stage 1 imputation was performed with CHB (Han Chinese in
Beijing, China) and JPT (Japanese in Tokyo, Japan) HapMap 2 panel as the reference using
program MACH v1.0 70 (see URLs). Stage 3 imputation was conducted with phased data of
JPT/CHS/CHD participants from the 1000 Genomes Project phase1 v3 as the reference
using program MACH v1.0 70 and minimac 71 (see URLs). Regional imputation of genotype
data from The Cancer Genome Atlas (TCGA) 30 (see URLs) was performed with the
GIANT ALL reference panel from the 1000 Genomes Project phase1 release v3 using
MACH v1.0 70 and minimac 71 (see URLs). To evaluate the imputation quality in our study,
we directly genotyped the ten newly identified risk variants in approximately 2,800 samples
included in stage 1. The concordance between imputed and genotyped data was very high,
with mean values ranging from 96.00% to 99.96% for the ten SNPs (Supplementary Table
20). For rs10849432, the imputation quality for the Aichi-1 study was relatively low (R2
=0.57), and thus data from this study were not included in our final analysis. We evaluated
population structure in studies included in stages 1 and 2 using principal components
analysis with EIGENSTRAT software 72 (see URLs). Based on adjusted regression models
including the first ten principal components, the genomic inflation factor λ was <1.04 in
each of the five studies included in stage 1 and 1.0368 in the meta-analysis of all five studies
(Supplementary Fig. 2). The λ was <1.05 in each of the three studies included in stage 2 and
1.0525 in the meta-analysis of all three studies (Supplementary Fig. 3). A rescaled inflation
statistic λ1000, representing an equivalent value of a study with 1,000 cases and 1,000
controls using the formula: λ1000 = 1 + 500 × (λ − 1) × (1/Ncases + 1/Ncontrols) 73, was 1.01
in both stages 1 and 2. These findings showed little evidence of population stratification in
our studies.
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Associations between SNPs and CRC risk were evaluated on the basis of the log-additive
model using mach2dat 70, PLINK version 1.0.7 74, R version 3.0.0 and SAS version 9.3 (for
all of these see URLs). Per-allele odds ratios (ORs) and 95% confidence intervals (CIs) were
derived from logistic regression models, adjusting for age, sex and the first ten principal
components when appropriate. Association analysis was conducted for each participating
study separately and a fixed-effects meta-analysis was conducted to obtain summary results
for each of the four stages and all stages combined with the inverse-variance method using
program METAL 75. SNPs showing an association at P <5×10−8 in the combined analysis of
all studies were considered genome-wide significant. We also performed stratified analyses
for the top SNPs by tumor anatomic site (colon and rectum), population (Chinese, Korean
and Japanese) and sex (men and women). We estimated heterogeneity across studies and
subgroups with a Cochran’s Q test 76, with P for heterogeneity <0.008 as statistically
significant considering multiple comparisons of six independent loci. Independent signals in
a locus were identified using stepwise logistic regression models conditioning on the top risk
variant we identified in each of the new loci using R software (see URLs). We estimated
haplotype frequencies using Haploview version 4.2 77 (see URLs) and conducted haplotype
association analysis for two loci (11q12.2 and 19q13.2) where two or more SNPs were
identified using SAS Genetics v9.3 with logistic regression models. Pairwise SNP-SNP
interactions between six top risk variants in the newly identified loci with P <5×10−8 and
also between these six SNPs and the risk variants in 25 previously reported loci were
evaluated using the maximal likelihood ratio test with inclusion of interaction terms into
logistic regression models. Interactions with P <0.00028 were considered statistically
significant with the adjustment of multiple comparisons of 180 tests.
The familial relative risk (λ) to offspring of an affected individual due to a single locus was
estimated using a log-additive model: λ=(pr2 +q) / (pr +q)2, where p is the frequency of the
risk allele, q = 1-p is the frequency of the reference allele, and r is the per-allele relative
risk 78. The proportion of the familial relative risk explained by this locus, assuming a
multiplicative interaction between markers in the locus and other loci, was calculated as:
log(λ)/ log (λo), where λo is the overall familial relative risk. λo is assigned to be 2.2 for
CRC estimated from a meta-analysis 79. Assuming that the risk associated with each locus
combine multiplicatively, the familial relative risks also multiply. Then the combined
contribution of the familial relative risks from multiple loci is equal to: ln(Πiλi)/ln(λ0).
We generated forest plots and Q-Q plots using R software (see URLs). Regional association
plots for SNPs in newly identified loci were generated using the website-based tool
LocusZoom version 1.1 80 (see URLs). Linkage equilibrium (LD) structure between SNPs
was determined on the basis of data from the 1000 Genomes Project Pilot 1 or HapMap 2 as
provided by the website-based tool SNAP 81 (see URLs) and plotted using Haploview,
SNAP and the UCSC Genome Browser (see URLs). LD blocks were defined using HapMap
recombination rates and hotspots 23. All the genomic coordinates are based on the National
Center for Biotechnology Information (NCBI), Build 36.
To identify putative functional variants for newly identified loci, we identified all SNPs in
LD (i.e., r2 > 0.5) with the risk variants using data from the 1000 Genomes Project 22 and
HapMap 2 23. We mapped the genomic locations of these SNPs to nonsynonymous sites,
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splice sites, promoters, nearGene-3 regions, nearGene-5 regions, three prime untranslated
regions (3′-UTR), five prime untranslated regions (5′-UTR), introns and intergenic regions.
We evaluated the potential functional effect of nonsynonymous SNPs using the prediction
algorithms SIFT 36 and PolyPhen-2 37 (see URLs). We predicted the putative function of
SNPs in promoters, nearGene-3 regions, nearGene-5 regions, 3′-UTR and 5′-UTR with
SNPinfo Web Server 45 (see URLs). We conducted analyses to evaluate the potential
regulatory effect of SNPs in non-coding regions on transcription using the Encyclopedia of
DNA Elements (ENCODE) tool HaploReg v2 82 and the UCSC Genome Browser (see
URLs) on the basis of their location within regions of promoter or enhancer activity, DNase
I hypersensitivity; local histone modifications, proteins bound to these regulatory sites, cis
expression quantitative trait loci (eQTL) and transcription factor binding motif. We obtained
additional functional evidence for these SNPs from the published literature.
We identified all genes that localize in a 1-mb window centered on the top risk variants in
our newly identified loci and including SNPs correlated (r2 > 0.5) with the top risk variants.
To determine whether these genes may explain the observed association in these loci, we
first examined genome-wide cis eQTL data in multiple tissues from four major eQTL
databases: the Blood eQTL browser 25, the eQTL Browser 26, the Genotype-Tissue
Expression project (GTEx) 27 and the Multiple Tissue Human Expression Resource project
(MuTHER) 28. The significance threshold for these analyses was set to P <0.008 to count
for six tests. Somatic mutations of these genes were evaluated using data from the Catalogue
of Somatic Mutations in Cancer (COSMIC) 29 (see URLs). Expression levels of these genes
in CRC cell lines were assessed using data from Gene Expression Atlas 31 (see URLs). To
correct for multiple comparisons of the 11 key genes, associations with a P < 0.0045 were
considered to be statistically significant. We searched the published literature for these genes
in relation to CRC from PubMed and OMIM (see URLs).
Expression analysis
We downloaded RNA sequencing (level 1) and SNP array (level 2) data for 364 colon
adenocarcinoma and 18 normal colon tissue samples from TCGA 30 (see URLs). To
quantify expression levels of candidate genes in the newly identified loci, we normalized
gene expression levels using the reads per kilobase of exon per million mapped reads
(RPKM) value as previously described 83. Expression differences between tumor and
normal samples for each gene were evaluated on the basis of the RPKM values with the
Wilcoxon rank sum test. Associations between gene RPKM value and SNP genotypes were
analyzed using a linear regression model including age and sex as covariates. We converted
the RPKM value of a gene to log scale for analysis if it was not normally distributed. We
considered P <0.0045 to be statistically significant with adjustment for testing of the 11 key
genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Forest plots for risk variants in the six newly identified loci
The six plots represent (a) rs704017, (b) rs11196172, (c) rs174537, (d) rs10849432, (e)
rs12603526 and (f) rs1800469. Per-allele ORs are presented, with the area of each box
proportional to the inverse variance weight of the estimate. Horizontal lines represent 95%
CIs. Diamonds represent summary ORs generated under a fixed-effects meta-analysis; width
of the diamonds corresponds to the 95% CIs. Unbroken vertical lines represent the null
value; broken vertical lines represent the summary ORs for all studies for each SNP.
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Figure 2. Association of selected risk variants identified in this study with gene expression in
colon tumor tissue
The three plots are for (a) rs11196172 and TCF7L2, (b) rs11196172 and VTI1A, and (c)
rs1535 and FADS2. Gene expression levels are represented by per kilobase of exon per
million mapped reads (RPKM) value based on the three genotypes of each SNP in red, blue
and green. The median RPKM values and the interquartile range for each SNP are presented
in the overlaid box plot. In (a) and (b), RPKM values are shown at normal scale, whereas
RPKM values in (c) are shown with a log scale due to departure from normal distribution.
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